Showing Results for
- Academic Journals (59)
Search Results
- 59
Academic Journals
- 59
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedTransfection of small RNAs (such as small interfering RNAs (siRNAs) and microRNAs (miRNAs)) into cells typically lowers expression of many genes. Unexpectedly, increased expression of genes also occurs. We investigated...
- 2From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedThe beginning of April marked the end for Irving, Texas-based DelSite. Although the company had FDA clearance for a phase 1 trial of its GelVac nasal powder H5N1 influenza vaccine, it had spent several months fruitlessly...
- 3From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedCells that resemble germ cells have been generated in vitro from embryonic stem cells, but the process is poorly understood and differentiation efficiencies are low. To improve these methods, it will be important to...
- 4From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedVertex Pharmaceuticals (Cambridge, MA, USA) has promoted Peter Mueller, executive vice president, drug innovation and realization and CSO, to executive vice president, global research and development and CSO. Mueller's...
- 5From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedGermany, home to the biggest swine population in Europe, is up in arms over a patent covering a marker-assisted test to breed meatier pigs. The patent covers a screening method to identify a polymorphism in the leptin...
- 6From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedAs new media proliferate and the public's trust and engagement in science are influenced by industry involvement in academic research, an interdisciplinary workshop provides some recommendations to enhance science...
- 7From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedIt s Monday, and your homework assignment I is due "within two days:' When do you have to hand it in--Wednesday? Or maybe Tuesday? Missing a deadline in school could be a problem but would not ordinarily cost money. In...
- 8From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedThe US Food and Drug Administration on April 24 approved Simponi, a secondgeneration tumor necrosis factor-α inhibitor, to treat three forms of arthritis. Simponi is a once-monthly subcutaneous injection for treating...
- 9From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedTaiwan's government has announced the launch of a $1.76 billion venture capital fund as part of a comprehensive 'biotechnology takeoff package' aimed at putting the country on Asia's biotech map. The National Development...
- 10From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedWe have modified the biotin switch assay for protein S-nitrosothiols (SNOs), using resin-assisted capture (SNO-RAC). Compared with existing methodologies, SNO-RAC requires fewer steps, detects high-mass S-nitrosylated...
- 11From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedOn April 3, a federal appeals court ruled in favor of Eli Lilly in Indianapolis, Indiana, capping a seven-year legal fight with Ariad Pharmaceuticals over its patent claims surrounding nuclear factor kappa B (NFκB). The...
- 12From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedTo the Editor: A news article in your February issue (1) reported that GM poplars developed by the group of Wout Boerjan at the Flanders Institute of Biotechnology (VIB) in Ghent were to move to the Netherlands to go...
- 13From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedInfluenza A virus leads to yearly epidemics and sporadic pandemics. Present prophylactic strategies focus on egg-grown, live, attenuated influenza vaccines (LAIVs), in which attenuation is generated by conferring...
- 14From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedSkyePharma (London) has appointed Thomas Werner as a new nonexecutive director. Werner is a senior-level pharmaceutical executive with over 26 years experience, most recently as managing director and senior vice...
- 15From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedGlaxoSmithKline (GSK) Biologicals reached an important milestone on March 30 in its effort to make up lost ground on rival vaccine maker Merck. Almost two years to the day after submitting a biologics license application...
- 16From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedWhen company management find themselves at odds with investors, things can get ugly very quickly. In March, Alameda, California--based Avigen had to defend itself against its biggest shareholder, the Biotechnology Value...
- 17From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedHydrogels are essential ingredients in current strategies for tissue engineering and cell delivery owing to their physical properties, which mimic aspects of natural extracellular matrix. As described recently in...
- 18From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedMultidrug transporters are the bane of pharmacologists as they diminish the efficacy of many drugs by pumping them out of bacteria and mammalian cells (1). The multidrug efflux pump P-glycoprotein (P-gp), for example,...
- 19From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedCorey Goodman has resigned from his position as president of Pfizer's Biotherapeutics and Bioinnovation Center (S. San Francisco, CA, USA) just 19 months after his hiring as part of Pfizer's effort to expand its push...
- 20From: Nature Biotechnology. (Vol. 27, Issue 6) Peer-ReviewedScientists at the US National Cancer Institute (NCI) in Bethesda, Maryland, have conducted the first phase 0 oncology trial, which they claim could help accelerate drug development. The NCI phase 0 study tested a single...